Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 17113187.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment of widespread moderate to severe atopic eczema remains a challenge. The therapeutic efficacy and modifications of the immune response during treatment of atopic eczema with efalizumab are so far unknown. We hereby report the clinical findings and characterize the inflammatory infiltrate during treatment of severe recalcitrant atopic eczema with efalizumab.
Medical subject headings
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Dermatitis, Atopic